Embedded Systems Requirements Verification Using HiLeS Designer

International audienceOne of the issues related to systems design is the early verification in first design steps: system specifications verification. Nowadays, it is common to use text-based specifications to begin a system design. However, these specifications cannot be verified until a software model is made. In this work, we show how can we use HiLeS Designer to model and verify, formally and by simulation an embedded system specification. This tool makes easier to build the model, using graphical concepts which are familiar to designers. It also helps to verify formally the structure and some logical behavior, and by simulation, it is possible to verify the consistence of the embedded system specification. We model and verify System Display Selector Requirements applying HiLeS Designer

Constructing a small modular stellarator in Latin America

https://www.scopus.com/inward/record.url?eid=2-s2.0-84938118149&partnerID=40&md5=1d385f1e177901beaf6f30228abdd67bThis paper aims at briefly describing the design and construction issues of the stellarator of Costa Rica 1 (SCR-1). The SCR-1 is a small modular stellarator for magnetic confinement of plasma developed by the Plasma Laboratory for Fusion Energy and Applications of the Instituto Tecnológico de Costa Rica (ITCR). SCR-1 will be a 2-field period small modular stellarator with an aspect ratio > 4.4; low shear configuration with core and edge rotational transform equal to 0.32 and 0.28; it will hold plasma in a 6061-T6 aluminum torus shaped vacuum vessel with an minor plasma radius 54.11 mm, a volume of 13.76 liters (0.01 m3), and major radius R = 238 mm. Plasma will be confined in the volume by on axis magnetic field 43.8 mT generated by 12 modular coils with 6 turns each, carrying a current of 767.8 A per turn providing a total toroidal field (TF) current of 4.6 kA-turn per coil. The coils will be supplied by a bank of cell batteries of 120 V. Typical length of the plasma pulse will be between 4 s to 10 s. The SCR-1 plasmas will be heated by ECH second harmonic at 2.45 GHz with a plasma density cut-off value of 7.45 × 1016 m-3. Two magnetrons with a maximum output power of 2 kW and 3 kW will be used. © Published under licence by IOP Publishing Ltd.Ad Astra Rocket Company,Instituto Tecnologico de Costa Rica,International Atomic Energy Agency (IAEA),Universidad Nacional de Costa Ric

Bisphenol A induces coronary endothelial cell necroptosis by activating RIP3/CamKII dependent pathway.

Epidemiological studies link long term exposure to xenoestrogen Bisphenol-A to adverse cardiovascular effects. Our previous results show that BPA induces hypertension by a mechanism involving CamKII activation and increased redox stress caused by eNOS uncoupling. Recently, CamKII sustained activation has been recognized as a central mediator of programmed cell death in cardiovascular diseases, including necroptosis. However, the role of necroptosis in cardiac response to BPA had not yet been explored. Mice exposed to BPA for 16 weeks showed altered heart function, electrical conduction, and increased blood pressure. Besides, a stress test showed ST-segment depression, indicative of cardiac ischemia. The hearts exhibited cardiac hypertrophy and reduced vascularization, interstitial edema, and large hemorrhagic foci accompanied by fibrinogen deposits. BPA initiated a cardiac inflammatory response, up-regulation of M1 macrophage polarization, and increased oxidative stress, coinciding with the increased expression of CamKII and the necroptotic effector RIP3. In addition, cell death was especially evident in coronary endothelial cells within hemorrhagic areas, and Evans blue extravasation indicated a vascular leak in response to Bisphenol-A. Consistent with the in vivo findings, BPA increased the necroptosis/apoptosis ratio, the expression of RIP3, and CamKII activation in endothelial cells. Necrostatin-1, an inhibitor of necroptosis, alleviated BPA induced cardiac dysfunction and prevented the inflammatory and hemorrhagic response in mice. Mechanistically, silencing of RIP3 reversed BPA-induced necroptosis and CamKII activation in endothelial cells, while inhibition of CamKII activation by KN-93 had no effect on RIP3 expression but decreased necroptotic cell death suggesting that BPA induced necroptosis is mediated by a RIP 3/CamKII dependent pathway. Our results reveal a novel pathogenic role of BPA on the coronary circulation. BPA induces endothelial cell necroptosis, promotes the weakening of coronary vascular wall, which caused internal ventricular hemorrhages, delaying the reparative process and ultimately leading to cardiac dysfunction.post-print4043 K

Density biases and temperature relations for DESIRED HII regions

We present a first study based on the analysis of the DEep Spectra of Ionized REgions Database (DESIRED). This is a compilation of 190 high signal-to-noise ratio optical spectra of HII regions and other photoionized nebulae, mostly observed with 8-10m telescopes and containing $\sim$29380 emission lines. We find that the electron density --$n_{\rm e}$-- of the objects is underestimated when [SII] $\lambda6731/\lambda6716$ and/or [OII] $\lambda3726/\lambda3729$ are the only density indicators available. This is produced by the non-linear density dependence of the indicators in the presence of density inhomogeneities. The average underestimate is $\sim 300$ cm$^{-3}$ in extragalactic HII regions, introducing systematic overestimates of $T_{\rm e}$([OII]) and $T_{\rm e}$([SII]) compared to $T_{\rm e}$([NII]). The high-sensitivity of [OII] $\lambda\lambda7319+20+30+31/\lambda\lambda3726+29$ and [SII] $\lambda\lambda4069+76/\lambda\lambda6716+31$ to density makes them more suitable for the diagnosis of the presence of high-density clumps. If $T_{\rm e}$([NII]) is adopted, the density underestimate has a small impact in the ionic abundances derived from optical spectra, being limited to up to $\sim$0.1 dex when auroral [SII] and/or [OII] lines are used. However, these density effects are critical for the analysis of infrared fine structure lines, such as those observed by the JWST in local star forming regions, implying strong underestimates of the ionic abundances. We present temperature relations between $T_{\rm e}$([OIII]), $T_{\rm e}$([ArIII]), $T_{\rm e}$([SIII]) and $T_{\rm e}$([NII]) for the extragalactic HII regions. We confirm a non-linear dependence between $T_{\rm e}$([OIII])-$T_{\rm e}$([NII]) due to a more rapid increase of $T_{\rm e}$([OIII]) at lower metallicities.Comment: Accepted for publication in MNRA

Evaluation of bacterial adherence of clinical isolates of Staphylococcus sp. using a competitive model: An in vitro approach to the "race for the surface" theory

Objectives Implant-related infection is one of the most devastating complications in orthopaedic surgery. Many surface and/or material modifications have been developed in order to minimise this problem; however, most of the in vitro studies did not evaluate bacterial adhesion in the presence of eukaryotic cells, as stated by the 'race for the surface' theory. Moreover, the adherence of numerous clinical strains with different initial concentrations has not been studied. Methods We describe a method for the study of bacterial adherence in the presence of preosteoblastic cells. For this purpose we mixed different concentrations of bacterial cells from collection and clinical strains of staphylococci isolated from implant-related infections with preosteoblastic cells, and analysed the minimal concentration of bacteria able to colonise the surface of the material with image analysis. Results Our results show that clinical strains adhere to the material surface at lower concentrations than collection strains. A destructive effect of bacteria on preosteoblastic cells was also detected, especially with higher concentrations of bacteria. Conclusions The method described herein can be used to evaluate the effect of surface modifications on bacterial adherence more accurately than conventional monoculture studies. Clinical strains behave differently than collection strains with respect to bacterial adherence.This work was funded by the following grants from the Spanish MINECO (MAT2013- 48224-C2-2-R and MAT2013-48224-C2-1-R). M. Martínez-Pérez reports funding received from EFORT 2015 congress: travel supported by PFIZER, which is related to this article. J. Esteban and E. Gómez-Barrena report funding received from several companies for travel, expenses and grants, none of which is related to this articl

Planeamiento territorial sostenible: un reto para el futuro de nuestras sociedades; criterios aplicados

In a large part of the 17 sustainable development objectives set as goals for humanity by the UN, sustainability can be glimpsed. As a result of the dominant socio-productive model, the only way to head towards more sustainable territories that allow achieving and maintaining the well-being of the world's population is to bear in mind the need to properly plan territorial development. This work reflects on this need and takes a step forward in the definition of the main criteria to achieve territorial sustainability at regional and local scales

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.

Background Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.post-print1360 K

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort

[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014‐October 2015). In total, 208 patients were included: 98 (47%) treatment‐experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count <75×10E9/mL (RR: 3.50, P=.019). In patients with MELD <10, type of NS5A inhibitor did not impact on SVR12 (94% vs 97%; adjusted RR: 0.49). Thirteen patients (6.3%) had serious adverse events, including three deaths (1.4%) and one therapy discontinuation (0.5%), higher in decompensated patients (16.7% vs 3.6%, P<.006). In patients with GT3 infection and cirrhosis, SVR12 rates were high with both SOF+DCV and SOF/LDV, with few serious adverse events

Small Bowel Enteroscopy - A Joint Clinical Guideline by the Spanish and Portuguese Small-Bowel Study Groups

The present evidence-based guidelines are focused on the use of device-assisted enteroscopy in the management of small-bowel diseases. A panel of experts selected by the Spanish and Portuguese small-bowel study groups reviewed the available evidence focusing on the main indications of this technique, its role in the management algorithm of each indication, and its diagnostic and therapeutic yield. A set of recommendations was issued accordingly.info:eu-repo/semantics/publishedVersio